Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Safety and Effectiveness of Sebetralstat for Short-Term Prevention Before Procedures in People With Hereditary Angioedema

This is a Phase 4, prospective, open-label trial to evaluate the safety and effectiveness of sebetralstat when used for STP for a qualifying procedures in patients 12 years of age or older with hereditary angioedema (HAE).

Participants needed: 100
Trial details
Phase: Phase 4Age: 12+Biological sex: AllType: InterventionalSponsor: KalVista Pharmaceuticals, Ltd.Updated: Jun 17, 2026
Eligibility criteria

Male or female patients ≥12 years of age at time of Screening [+8]

A clinically significant history of poor response to bradykinin receptor 2 block... [+8]

Status: Available

Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Hereditary Angioedema (HAE) pediatric (ages 2-11) post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.

Trial details
Age: 2-11Biological sex: AllType: Expanded AccessSponsor: KalVista Pharmaceuticals, Ltd.Updated: May 28, 2026Locations: 4
Eligibility criteria

Male or female patients 2 to 11 years of age. [+2]

Confirmed diagnosis of HAE with nC1-INH or acquired angioedema [+6]